エイズアイ・イスラエル株式会社
基本情報
サイト
事業内容
関連会社
| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
| Eisai China Inc. | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
関連図
沿革
Eisai's founder, Toyoji Naito, is born on August 15 in Ito, a village in Fukui, central Japan. He is the sixth child and third son of Kikuji Naito and his wife, Fuji.![]()
Sakuragaoka Laboratory Co., Ltd. launches vitamin E product : Juvela : through Tanabe Motosaburo Store Co., Ltd. Its chocolate-brown coating, “hard outside, soft inside” pellets and stylish packaging garners much attention at the time. : Juvela : becomes the laboratory's first success. : Sakuragaoka Laboratory Co., Ltd. launches : Sampon : , Japan's first sanitary tampon, through Tanabe Motosaburo Store Co., Ltd.![]()
Nihon Eisai Co., Ltd., Eisai Co., Ltd.'s immediate predecessor, is established in Saitama, eastern Japan. : “Origin of the Eisai Logomark”![]()
Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merge under the name Nihon Eisai Co., Ltd.![]()
Nihon Eisai Co., Ltd.'s contraceptive suppository : Sampoon : , researched and developed during Japan's postwar baby boom, receives official approval from the Japanese government. : “Eisai Advertising Through the Years” : Nihon Eisai Co., Ltd. launches cardiotonic : Neophyllin : in Japan.![]()
Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product : Chocola BB Tablets : in Japan. : Nihon Eisai Co., Ltd. launches motion sickness remedy : Travelmin : in Japan.![]()
The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today. : “Origin of the Eisai Logomark”![]()
Eisai rolls out its first three-year mid-term plan. : Eisai's Head Office building is completed in Tokyo.![]()
Eisai opens its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan. : Eisai is publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges. : Gastrointestinal remedies : Saclon : and : Saclon Tablets : , recognizable for their distinct green hue even today, are launched in Japan.![]()
Toyoji Naito receives the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan. : The Tokyo Olympics take place.![]()
The Kawashima Plant is completed in Gifu, central Japan. Kawashima Plant opening ceremony. Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president. A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.![]()
PT Eisai Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia. Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.![]()
Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.![]()
Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively. Metabolic cardiotonic : Neuquinon : is launched in Japan.![]()
Eisai's founder Toyoji Naito passes away at age 89. Peripheral neuropathy treatment : Methycobal : is launched in Japan.![]()
Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore.![]()
Eisai U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States. The Misato Plant commences pharmaceutical manufacturing in Saitama. Large-scale automated sugar-coating equipment (pan diameter of up to 170 cm) at the Misato Plant.![]()
Eisai Chemical Co., Ltd. (now Eisai's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs).![]()
Eisai has supported of the Health and Medical Care Contributions Awards, which are presented to healthcare professionals who have contributed significantly to improving access to healthcare in difficult-to-reach areas from 1987 to 2015.![]()
Eisai Research Institute of Boston, Inc. (now the Boston Research Institute) is established as a discovery research subsidiary in Massachusetts, the United States.![]()
President Yuji Naito steps down from office and assumes the role of chairman; Vice President Haruo Naito is appointed president of Eisai.![]()
Eisai America, Inc. is established as a clinical research subsidiary in New Jersey, the United States.![]()
Eisai Machinery GmbH is established as a pharmaceutical machinery sales subsidiary in Cologne, former West Germany.![]()
Eisai (Thailand) Marketing Co., Ltd. is established as a pharmaceutical sales subsidiary in Bangkok, Thailand.![]()
Eisai London Research Laboratories, Ltd. is established as a discovery research subsidiary attached to University College London in the United Kingdom.![]()
Shenyang Eisai Pharmaceutical Co., Ltd. is established as a Chinese–foreign contractual joint venture in pharmaceutical manufacturing and sales in Shenyang, China.![]()
Eisai Corporation of North America is established as a holding company in New Jersey, the United States.![]()
Eisai London Research Laboratories, Ltd. is completed in the United Kingdom to form an Eisai Group multipolar R&D network spanning Japan, America and Europe.![]()
Eisai London Research Laboratories opening ceremony in 1993 attended by the United Kingdom's Princess Royal, Princess Anne![]()
Eisai Suzhou Pharmaceutical Co., Ltd. is established as a pharmaceutical manufacturing and sales subsidiary in Jiangsu, China.![]()
Eisai Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom.![]()
Eisai Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India.![]()
Eisai Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery.![]()
The European Knowledge Centre (now EMEA Knowledge Centre) opens as a European strategic base in Hertfordshire, the United Kingdom.![]()
EMEA Knowledge Centre: The Eisai Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D.![]()
Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations.![]()
The Eisai Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India.![]()
The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award.![]()
Koishikawa Knowledge Center: Eisai Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada.![]()
Production headquarters transforms to a global “Eisai Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing.![]()
Eisai (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China.![]()
Eisai signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge.![]()
Eisai Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.![]()
Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.![]()
Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).![]()
Eisai Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa.![]()
Eisai signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases.![]()